JP2024535431A5 - - Google Patents
Info
- Publication number
- JP2024535431A5 JP2024535431A5 JP2024519055A JP2024519055A JP2024535431A5 JP 2024535431 A5 JP2024535431 A5 JP 2024535431A5 JP 2024519055 A JP2024519055 A JP 2024519055A JP 2024519055 A JP2024519055 A JP 2024519055A JP 2024535431 A5 JP2024535431 A5 JP 2024535431A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- scaffold
- sequence number
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163249553P | 2021-09-28 | 2021-09-28 | |
| US63/249,553 | 2021-09-28 | ||
| US202263375282P | 2022-09-12 | 2022-09-12 | |
| US63/375,282 | 2022-09-12 | ||
| PCT/US2022/077182 WO2023056297A1 (en) | 2021-09-28 | 2022-09-28 | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535431A JP2024535431A (ja) | 2024-09-30 |
| JP2024535431A5 true JP2024535431A5 (https=) | 2025-10-07 |
Family
ID=84360925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519055A Pending JP2024535431A (ja) | 2021-09-28 | 2022-09-28 | シェーグレン症候群の治療及び予防におけるｃｄ４０ｌ特異的ｔｎ３由来足場 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240383991A1 (https=) |
| EP (1) | EP4408455A1 (https=) |
| JP (1) | JP2024535431A (https=) |
| KR (1) | KR20240101563A9 (https=) |
| AU (1) | AU2022358509A1 (https=) |
| CA (1) | CA3230926A1 (https=) |
| CL (2) | CL2024000881A1 (https=) |
| IL (1) | IL311710A (https=) |
| MA (1) | MA65537A1 (https=) |
| MX (1) | MX2024003954A (https=) |
| WO (1) | WO2023056297A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024152001A1 (en) * | 2023-01-13 | 2024-07-18 | Viela Bio, Inc. | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome |
| KR20250162587A (ko) * | 2023-03-28 | 2025-11-18 | 비엘라 바이오, 인크. | 쇼그렌 증후군의 치료 및 예방을 위한 cd40l 특이적 tn3 유래 스캐폴드 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200074993A (ko) * | 2017-11-03 | 2020-06-25 | 노파르티스 아게 | 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체 |
| KR20260016618A (ko) * | 2018-09-26 | 2026-02-03 | 비엘라 바이오, 인크. | Cd40l 길항제 및 이의 용도 |
-
2022
- 2022-09-28 MA MA65537A patent/MA65537A1/fr unknown
- 2022-09-28 JP JP2024519055A patent/JP2024535431A/ja active Pending
- 2022-09-28 KR KR1020247013785A patent/KR20240101563A9/ko active Pending
- 2022-09-28 AU AU2022358509A patent/AU2022358509A1/en active Pending
- 2022-09-28 EP EP22809606.1A patent/EP4408455A1/en active Pending
- 2022-09-28 CA CA3230926A patent/CA3230926A1/en active Pending
- 2022-09-28 MX MX2024003954A patent/MX2024003954A/es unknown
- 2022-09-28 IL IL311710A patent/IL311710A/en unknown
- 2022-09-28 WO PCT/US2022/077182 patent/WO2023056297A1/en not_active Ceased
-
2024
- 2024-03-21 US US18/612,452 patent/US20240383991A1/en active Pending
- 2024-03-26 CL CL2024000881A patent/CL2024000881A1/es unknown
-
2025
- 2025-03-03 CL CL2025000581A patent/CL2025000581A1/es unknown
- 2025-09-09 US US19/323,227 patent/US20260070997A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI241913B (en) | Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C | |
| JP2023052458A5 (https=) | ||
| Dunnick et al. | Clinical trials with exogenous interferon: summary of a meeting | |
| JP2022538237A5 (https=) | ||
| JP2024535431A5 (https=) | ||
| HUP0301444A2 (hu) | Ribavirin és pegilezett alfa-interferon alkalmazása HCV fertőzés kezelésére szolgáló gyógyszerkészítmény előállítására | |
| BR112021008778A2 (pt) | Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn | |
| WO1998005350A1 (en) | Materials and methods for treatment of plaquing diseases | |
| CN101878037A (zh) | 能够中和乙型肝炎病毒的人抗体在预防或治疗乙型肝炎病毒感染中的用途 | |
| EP0230574A2 (en) | Pharmaceutical compositions against infections caused by LAV/HTLV III virus and the use thereof | |
| JP2023531682A (ja) | Ｄ型肝炎ウイルス感染の処置のための組成物および方法 | |
| US20030008875A1 (en) | Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system | |
| JP2005506345A5 (https=) | ||
| EP4584295A1 (en) | Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies | |
| JPH11501310A (ja) | レトロウイルスの調節タンパク質から誘導された無毒の免疫原、抗体、製造方法およびそれらを含んでなる医薬組成物 | |
| KR20110053327A (ko) | 텔라프레비르 투여 방식 | |
| JP2022514561A5 (https=) | ||
| KR20250024800A (ko) | A형 및 b형 혈우병의 치료를 위한 피투시란 | |
| AU2021382954B2 (en) | Pharmaceutical composition, pharmaceutical combined formulation, and combined formulation kit for prevention or treatment of chronic hepatitis b, each comprising, as active ingredient, oral antiviral agent and therapeutic vaccine including lipopeptide and poly(i:c) adjuvant | |
| JP2025509568A5 (https=) | ||
| AU2005291741A1 (en) | Type I interferon blocking agents for prevention and treatment of psoriasis | |
| JP2024540294A5 (https=) | ||
| JP2024534012A5 (https=) | ||
| JP2024519904A5 (https=) | ||
| AU2023342527A1 (en) | Treating hiv with cabotegravir and rilpivirine in pediatric patients |